锂相关性肾衰竭:预测因素与结局
本研究基于澳大利亚和新西兰透析与移植登记(ANZDATA)的回顾性研究,比较了437例锂相关性肾衰竭患者与1280例非锂相关性肾衰竭对照。锂相关性肾衰竭患者开始肾脏替代治疗时年龄更大、女性及欧洲裔比例更高、社会经济地位更高、合并症更少,但肾移植率更低,两组生存率无差异。
要点
- 锂相关性肾衰竭患者开始KRT时年龄更大(62±10 vs 58±15岁,P<0.001)。
- 该人群女性(63% vs 40%)、欧洲裔(93% vs 68%)比例更高,合并症更少。
- 肾移植率更低(21% vs 27%,P=0.008),但两组生存率无差异。
核心结论
- 锂相关性肾衰竭患者是一个独特队列,多为老年女性、欧洲裔、高社会经济地位且合并症较少,但生存率与非锂相关性肾衰竭无差异,肾移植率较低。
研究设计与样本
- 回顾性研究,使用澳大利亚和新西兰透析与移植登记(ANZDATA)数据,纳入437例锂相关性肾衰竭患者与1280例非锂相关性肾衰竭对照。
主要发现
- 锂相关性肾衰竭患者开始KRT年龄更大(62±10 vs 58±15岁,P<0.001),女性比例更高(63% vs 40%,P<0.001),欧洲裔比例更高(93% vs 68%,P<0.001),社会经济地位更高(P<0.001)。
- 锂相关性肾衰竭患者冠心病(17% vs 37%,P<0.001)、外周血管疾病(7% vs 25%,P<0.001)、脑血管疾病(8% vs 14%,P=0.004)和糖尿病(16% vs 47%,P<0.001)患病率更低。
- 首次KRT模式无差异,但肾移植率(21% vs 27%,P=0.008)和再移植率(0.2% vs 3%,P=0.001)更低,首次移植等待时间更短(20个月 vs 29个月,P=0.02)。
- 至少1次排斥反应发生率两组相当(21% vs 22%,P=0.85),且无论KRT模式如何,两组生存率无差异。
临床怎么用
- 临床应认识到锂相关性肾衰竭患者移植率较低,需进一步探索移植障碍。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Despite the widespread use of lithium for bipolar disorders and depression, little is known about the characteristics of patients with lithium-associated kidney failure receiving kidney replacement therapy (KRT). METHODS: We conducted a retrospective study using the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) to investigate the predictors and outcomes of patients with lithium-associated kidney failure receiving KRT. RESULTS: A total of 437 patients with lithium-associated kidney failure were compared to 1280 ANZDATA allocated controls of patients with kidney failure not associated with lithium. Patients with lithium-associated kidney failure commenced KRT at significantly older age (62 ± 10 vs. 58 ± 15 years; P < 0.001) and were more likely to be European (93% vs. 68%, P < 0.001), to be female (63% vs. 40%, P < 0.001), and to live in a postcode with a higher socioeconomic status (SES) (P < 0.001). In patients with lithium-associated kidney failure, there were lower rates of coronary artery disease (17% vs. 37%, P < 0.001), peripheral vascular disease (7% vs. 25%, P < 0.001), cerebrovascular disease (8% vs. 14%, P = 0.004) and diabetes mellitus (16% vs. 47%, P < 0.001). There were no differences between first KRT modality, although kidney transplantation and retransplantation rates were lower (21% vs. 27%, P = 0.008; 0.2% vs 3%, P = 0.001) with shorter wait-times to first transplantation (20 months vs. 29 months, P = 0.02) in the patients with lithium-associated kidney failure. Rates of at least 1 rejection episode was comparable (21% vs. 22%, P = 0.85) between the 2 groups. In addition, there were no survival differences regardless of KRT modality between the 2 groups. CONCLUSION: Lithium-associated kidney failure represents a unique cohort which is predominantly older, female, European, with a higher SES and less comorbidities. Despite this, there are no differences in survival. Given the lower rate of transplantation, barriers to transplantation need further exploration.
引用
- Qian E, Sud K, Lee V, et al. Lithium-Associated Kidney Failure: Predictors and Outcomes. Kidney Int Rep. 2024. PMID: 38707830. doi:10.1016/j.ekir.2024.01.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。